Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2019 Apr 12

PMID 30971460

Citations 91

Authors

Romney M Humphries

April N Abbott

Janet A Hindler

Affiliations

Soon will be listed here.

Abstract

The Clinical and Laboratory Standards Institute (CLSI) has revised several breakpoints since 2010 for bacteria that grow aerobically. In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the and , daptomycin breakpoints for spp., and ceftaroline breakpoints for Implementation of the revisions is a challenge for all laboratories, as not all systems have FDA clearance for the revised (current) breakpoints, compounded by the need for laboratories to perform validation studies and to make updates to laboratory information system/electronic medical record builds in the setting of limited information technology infrastructure. This minireview describes the breakpoint revisions in the M100 supplement since 2010 and strategies for the laboratory on how to best adopt these in clinical testing.

Citing Articles

Characterization and genomic analysis of a bacteriophage UHP46 infecting mastitis-causing .

Najeeb S, Khan I, Muhammad J, Jahangir M, Alvi I, Abbas A Front Microbiol. 2025; 16:1496919.

PMID: 40012776 PMC: 11861072. DOI: 10.3389/fmicb.2025.1496919.

Bicarbonate Within: A Hidden Modulator of Antibiotic Susceptibility.

Ersoy S, Rose W, Proctor R Antibiotics (Basel). 2025; 14(1).

PMID: 39858381 PMC: 11760860. DOI: 10.3390/antibiotics14010096.

Azotobacter biodiversity in Egypt using microbiological, biochemical, and molecular-biology multidisciplinary approach.

Kenawy A, Khalil A, Ali B, El-Deeb N, Haddad A Genetica. 2025; 153(1):9.

PMID: 39777558 DOI: 10.1007/s10709-024-00224-1.

evaluation of anti-microbial efficacy of and its constituents on oral biofilms.

Sethi G, Sood S, Bhardwaj S, Jain A J Indian Soc Periodontol. 2025; 28(3):304-311.

PMID: 39742064 PMC: 11684565. DOI: 10.4103/jisp.jisp_540_23.

Investigation of Antibiotic Resistance of Associated with Farm Animal Feces with Participation of Citizen Scientists.

Timofeeva A, Galyamova M, Krivosheev D, Karabanov S, Sedykh S Microorganisms. 2024; 12(11).

PMID: 39597696 PMC: 11596788. DOI: 10.3390/microorganisms12112308.

References

Tam V, Gamez E, Weston J, Gerard L, LaRocco M, Caeiro J . Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008; 46(6):862-7. DOI: 10.1086/528712. View

Gupta K, Hooton T, Naber K, Wullt B, Colgan R, Miller L . International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5):e103-20. DOI: 10.1093/cid/ciq257. View

Humphries R, Fang F, Aarestrup F, Hindler J . In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis. 2012; 55(8):1107-13. DOI: 10.1093/cid/cis600. View

Dudley M, Ambrose P, Bhavnani S, Craig W, Ferraro M, Jones R . Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam. Clin Infect Dis. 2013; 56(9):1301-9. DOI: 10.1093/cid/cit017. View

Schuetz A, Brasso W, Crandon J, Hardy D, Jenkins S, Jones R . Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae. Diagn Microbiol Infect Dis. 2013; 77(4):381-2. DOI: 10.1016/j.diagmicrobio.2013.08.024. View

Humphries R, Pollett S, Sakoulas G . A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev. 2013; 26(4):759-80. PMC: 3811228. DOI: 10.1128/CMR.00030-13. View

Deak E, Hindler J, Skov R, Sjolund-Karlsson M, Sokovic A, Humphries R . Performance of Etest and disk diffusion for detection of ciprofloxacin and levofloxacin resistance in Salmonella enterica. J Clin Microbiol. 2014; 53(1):298-301. PMC: 4290941. DOI: 10.1128/JCM.02715-14. View

Patel T, Nagel J . Clinical outcomes of Enterobacteriaceae infections stratified by carbapenem MICs. J Clin Microbiol. 2014; 53(1):201-5. PMC: 4290923. DOI: 10.1128/JCM.03057-14. View

Chea N, Bulens S, Kongphet-Tran T, Lynfield R, Shaw K, Vagnone P . Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae. Emerg Infect Dis. 2015; 21(9):1611-6. PMC: 4550143. DOI: 10.3201/eid2109.150198. View

10.

Deak E, Skov R, Hindler J, Humphries R . Evaluation of Surrogate Disk Tests for Detection of Ciprofloxacin and Levofloxacin Resistance in Clinical Isolates of Salmonella enterica. J Clin Microbiol. 2015; 53(11):3405-10. PMC: 4609702. DOI: 10.1128/JCM.01393-15. View

11.

Jorgensen J . Putting the New CLSI Cephalosporin and Carbapenem Breakpoint Changes Into Practice in Clinical Microbiology Laboratories. J Pediatric Infect Dis Soc. 2015; 1(2):169-70. DOI: 10.1093/jpids/pis047. View

12.

Langford B, Seah J, Chan A, Downing M, Johnstone J, Matukas L . Antimicrobial Stewardship in the Microbiology Laboratory: Impact of Selective Susceptibility Reporting on Ciprofloxacin Utilization and Susceptibility of Gram-Negative Isolates to Ciprofloxacin in a Hospital Setting. J Clin Microbiol. 2016; 54(9):2343-7. PMC: 5005502. DOI: 10.1128/JCM.00950-16. View

13.

Bartsch S, Huang S, Wong K, Slayton R, McKinnell J, Sahm D . Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae. J Clin Microbiol. 2016; 54(11):2757-2762. PMC: 5078554. DOI: 10.1128/JCM.00635-16. View

14.

Humphries R, Hindler J, Epson E, Horwich-Scholefield S, Miller L, Mendez J . Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?. Clin Infect Dis. 2017; 66(7):1061-1067. DOI: 10.1093/cid/cix942. View

15.

Humphries R, Ferraro M, Hindler J . Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls. J Clin Microbiol. 2018; 56(5). PMC: 5925699. DOI: 10.1128/JCM.00139-18. View

16.

Tandan M, Cormican M, Vellinga A . Adverse events of fluoroquinolones vs. other antimicrobials prescribed in primary care: A systematic review and meta-analysis of randomized controlled trials. Int J Antimicrob Agents. 2018; 52(5):529-540. DOI: 10.1016/j.ijantimicag.2018.04.014. View

17.

Humphries R, Hindler J, Ferraro M, Mathers A . Twenty-first Century Cures Act and Antimicrobial Susceptibility Testing: Clinical Implications in the Era of Multidrug Resistance. Clin Infect Dis. 2018; 67(7):1132-1138. DOI: 10.1093/cid/ciy432. View

18.

Campeau S, Schuetz A, Kohner P, Arias C, Hemarajata P, Bard J . Variability of Daptomycin MIC Values for Enterococcus faecium When Measured by Reference Broth Microdilution and Gradient Diffusion Tests. Antimicrob Agents Chemother. 2018; 62(9). PMC: 6125562. DOI: 10.1128/AAC.00745-18. View

19.

Kidd J, Abdelraouf K, Asempa T, Humphries R, Nicolau D . Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model. Antimicrob Agents Chemother. 2018; 62(10). PMC: 6153845. DOI: 10.1128/AAC.00506-18. View

20.

Harris P, Tambyah P, Lye D, Mo Y, Lee T, Yilmaz M . Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA. 2018; 320(10):984-994. PMC: 6143100. DOI: 10.1001/jama.2018.12163. View